Open label study provides evidence of AP-Bio’s immunomodulatory benefits

A recent human study has provided some validation of the immunomodulatory benefits of a standardized extract of Andrographis paniculata, called AP-Bio.

A recent human study published in the Journal of Ayurveda and Integrative Medicine has provided some validation of the immunomodulatory benefits of a standardized extract of Andrographis paniculata, called AP-Bio (from Natural Remedies, based in Bangalore, India). In Europe the ingredient is known as KalmCold. In the open-label, single-center study, 21 healthy subjects took 200 mg of the Andrographis paniculata extract daily for 30 days. Subjects were evaluated at baseline, day 3, day 7, and day 30. Results showed that subjects had significant increases in T cells and T helper cells at day 7 and 30, as well as significant increases in interferon gamma, interleukin-4, and decrease in interleukin-2 at day 30.

“AP-Bio is the only Andrographis standardized to seven phytoconstituents: andrographolide (30%), isoandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, androgapanin, skullcapflavone-1 and 7-O-methylwogonin,” said Deepak Mundkinajeddu, PhD, Natural Remedies’ Head of research and development, in a press release. “This full profile of actives makes AP-Bio® a potent Andrographis for a variety of immune-support formulas.”

“As consumers look to faster onset of action for their immune health needs, AP-Bio provides a safe, natural, science-backed and sustainable solution,” said Abey Thomas, head of global marketing for Natural Remedies. “Consumers can feel good not only about the science behind AP-Bio’s immune support properties but that it is ethically and sustainably cultivated, harvested and processed.”

AIDP is the exclusive distribution partner for AP-Bio in the U.S. and Canada.

Reference

  1. Rajanna M et al. “Immunomodulatory effects of Andrographis paniculata extract in healthy adults – An open-label study.” Journal of Ayurveda and Integrative Medicine, vol. 12, no.3 (2021): 529-534